NEW PHARMACEUTICAL INVENTION INDEX - WHO'S IN THE TOP 10?
Since 2014, IDEA Pharma has issued the Pharmaceutical Innovation Index, ranking major pharma companies by their ability to add or extract value from their pipeline. For the first time this year, it is joined by the Pharmaceutical Invention Index--a more forward-looking list tracking who is investing time and resources in new and important medicines.
AstraZeneca tops this year’s list with a wide range of novel medicines.
The index looks at four key metrics: the proportion of pipeline to marketed drugs, the number of trials of brand-new agents, the proportion of ‘novel’ regulatory designations, and the company’s R&D investments.
These factors are assigned numerical metrics based on a variety of data and then all are computed together to produce an overall score for the company, which is then used to decide its ranking. This year’s scores were:
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
AstraZeneca scored well across all metrics, owing to their large pool of new drug trials, high ratio of pipeline to marketed drugs, and strong record of R&D investment, among other measurable improvements.
While invention measures the discovery and development of useful medicines, innovation refers to a company’s commitment and ability to deliver those inventions to patients. IDEA has lauded AstraZeneca’s marked upgrades in both departments.
NOVEMBER 2019 | MANE LIFE SCIENCES| 7